EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, VSTM: Verastem Inc

06 Nov 25 17:20
LAST:

7.930

CHANGE:
 0.23		OPEN:
8.200		HIGH:
8.290		ASK:
1.550		VOLUME:
2.55M
CHG(%):
2.82		PREV:
8.160		LOW:
7.730		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 258.2008.2907.7307.9302.55M
05 Nov 258.1008.5507.9958.1603.57M
04 Nov 259.1109.2797.5507.9108.51M
03 Nov 259.36010.0909.2909.9003.25M
31 Oct 259.2209.4709.1009.4501.8M
30 Oct 258.8209.4308.7309.2303.05M
29 Oct 258.9109.0358.5808.8001.45M
28 Oct 258.7009.1608.5008.8502.11M
27 Oct 258.0509.0108.0508.7204.43M
24 Oct 257.9208.3607.7507.9501.63M

COMPANY PROFILE

Name:Verastem Inc
About:Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:117 Kendrick Street, Needham, MA, United States, 02494
Website:https://www.verastem.com
CUSIP:92337C104
CIK:0001526119
ISIN:US92337C2035
FIGI:BBG001J2LSK5

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:8.679.3%
MA10:8.699.6%
MA20:8.689.4%
MA50:9.0514.1%
MA100:7.535.3%
MA200:6.9713.8%
STO9:0.92 
STO14:5.26 
RSI14:39.37 
WPR14:-94.26 
MTM14:-0.09
ROC14:-0.01 
ATR:0.83 
Week High:10.0927.2%
Week Low:7.555.0%
Month High:10.0927.2%
Month Low:6.9813.8%
Year High:11.2541.8%
Year Low:3.46129.5%
Volatility:7.05 

RECENT SPLITS

Date Ratio
01 Jun 20231-12